Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

DNA immunization against tissue-restricted antigens enhances tumor immunity after allogeneic hemopoietic stem cell transplantation.

Perales MA, Diab A, Cohen AD, Huggins DW, Guevara-PatiƱo JA, Hubbard VM, Engelhorn ME, Kochman AA, Eng JM, Mortazavi F, Alpdogan O, Terwey TH, Heller G, Wolchok JD, Houghton AN, van den Brink MR.

J Immunol. 2006 Sep 15;177(6):4159-67.

2.

Tumor cell vaccine elicits potent antitumor immunity after allogeneic T-cell-depleted bone marrow transplantation.

Teshima T, Mach N, Hill GR, Pan L, Gillessen S, Dranoff G, Ferrara JL.

Cancer Res. 2001 Jan 1;61(1):162-71.

3.

Donor leukocyte infusion from immunized donors increases tumor vaccine efficacy after allogeneic bone marrow transplantation.

Teshima T, Liu C, Lowler KP, Dranoff G, Ferrara JL.

Cancer Res. 2002 Feb 1;62(3):796-800.

5.
6.

New strategies in allogeneic stem cell transplantation: immunotherapy using irradiated allogeneic T cells.

Waller EK, Boyer M.

Bone Marrow Transplant. 2000 May;25 Suppl 2:S20-4.

PMID:
10933181
7.

Flagellin, a TLR5 agonist, reduces graft-versus-host disease in allogeneic hematopoietic stem cell transplantation recipients while enhancing antiviral immunity.

Hossain MS, Jaye DL, Pollack BP, Farris AB, Tselanyane ML, David E, Roback JD, Gewirtz AT, Waller EK.

J Immunol. 2011 Nov 15;187(10):5130-40. doi: 10.4049/jimmunol.1101334. Epub 2011 Oct 17.

8.
9.
11.

Enhanced immune reconstitution by sex steroid ablation following allogeneic hemopoietic stem cell transplantation.

Goldberg GL, Alpdogan O, Muriglan SJ, Hammett MV, Milton MK, Eng JM, Hubbard VM, Kochman A, Willis LM, Greenberg AS, Tjoe KH, Sutherland JS, Chidgey A, van den Brink MR, Boyd RL.

J Immunol. 2007 Jun 1;178(11):7473-84.

12.

Recipient leukocyte infusion enhances the local and systemic graft-versus-neuroblastoma effect of allogeneic bone marrow transplantation in mice.

Willems L, Fevery S, Sprangers B, Rutgeerts O, Lenaerts C, Ibrahimi A, Gijsbers R, Van Gool S, Waer M, Billiau AD.

Cancer Immunol Immunother. 2013 Nov;62(11):1733-44. doi: 10.1007/s00262-013-1479-6. Epub 2013 Oct 1.

PMID:
24081484
14.

Antigen and lymphopenia-driven donor T cells are differentially diminished by post-transplantation administration of cyclophosphamide after hematopoietic cell transplantation.

Ross D, Jones M, Komanduri K, Levy RB.

Biol Blood Marrow Transplant. 2013 Oct;19(10):1430-8. doi: 10.1016/j.bbmt.2013.06.019. Epub 2013 Jun 29.

15.

Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.

Chen G, Wu D, Wang Y, Cen J, Feng Y, Sun A, Tang X, Chang H, Zhu Z.

Eur J Haematol. 2008 Sep;81(3):226-35. doi: 10.1111/j.1600-0609.2008.01108.x. Epub 2008 Jun 28.

PMID:
18573173
16.

Irradiated donor leukocytes promote engraftment of allogeneic bone marrow in major histocompatibility complex mismatched recipients without causing graft-versus-host disease.

Waller EK, Ship AM, Mittelstaedt S, Murray TW, Carter R, Kakhniashvili I, Lonial S, Holden JT, Boyer MW.

Blood. 1999 Nov 1;94(9):3222-33.

17.

Graft-versus-host disease after allogeneic hematopoietic stem cell transplantation induces a CD8+ T cell-mediated graft-versus-tumor effect that is independent of the recognition of alloantigenic tumor targets.

Stelljes M, Strothotte R, Pauels HG, Poremba C, Milse M, Specht C, Albring J, Bisping G, Scheffold C, Kammertoens T, Oelmann E, Silling G, Berdel WE, Kienast J.

Blood. 2004 Aug 15;104(4):1210-6. Epub 2004 Apr 15.

18.

Allogeneic MHC gene transfer enhances antitumor activity of allogeneic hematopoietic stem cell transplantation without exacerbating graft-versus-host disease.

Ohashi M, Kobayashi A, Hara H, Miura Y, Yoshida K, Kushida M, Ikarashi Y, Mandai M, Kitajima M, Yoshida T, Aoki K.

Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2208-15.

19.

Ceacam1 separates graft-versus-host-disease from graft-versus-tumor activity after experimental allogeneic bone marrow transplantation.

Lu SX, Kappel LW, Charbonneau-Allard AM, Atallah R, Holland AM, Turbide C, Hubbard VM, Rotolo JA, Smith M, Suh D, King C, Rao UK, Yim N, Bautista JL, Jenq RR, Penack O, Na IK, Liu C, Murphy G, Alpdogan O, Blumberg RS, Macian F, Holmes KV, Beauchemin N, van den Brink MR.

PLoS One. 2011;6(7):e21611. doi: 10.1371/journal.pone.0021611. Epub 2011 Jul 6.

20.

Alloreactive memory T cells are responsible for the persistence of graft-versus-host disease.

Zhang Y, Joe G, Hexner E, Zhu J, Emerson SG.

J Immunol. 2005 Mar 1;174(5):3051-8.

Supplemental Content

Support Center